Deferiprone – the trial
Dr David Devos has led a Europe-wide consortia of neurologists and Parkinson’s specialists to secure funding from the EU’s Horizon 2020 programme to run a clinical trial through 28 centres across Europe to understand the efficacy of deferiprone in people with Parkinson’s.
It is hoped that this trial will demonstrate for the first time in a large phase ll, multicentre, parallel-group, placebo-controlled, randomly selected trial that iron chelation with the drug deferiprone will slow down the progression Parkinson’s. A nine month treatment period will be followed by a one month post-treatment monitoring period in order to assess the disease-modifying effect in the absence of deferiprone versus placebo. The Movement Disorders Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) will be used which encompasses measurement of movement, cognition behaviour and activities of daily living.
We expect this trial to observe a significantly lower MDS-UPDRS score relative to the control group. This will enable a demonstration of the efficacy of iron chelation as a treatment to slow the progression of Parkinson’s. We hope that the findings of this trial will be widely disseminated in order to promote and support the clinical development of deferiprone and other selected iron chelators for the treatment of Parkinson’s.